Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Cytomx Therapeutics Inc

Start price
Target price
Perf. (%)
€2.59
06.02.23
€4.00
31.12.25
-40.15%
05.05.23

Could be very worthwhile Investment >20% year
buy
Blue Apron Holdings Inc.

Start price
Target price
Perf. (%)
€15.31
06.02.23
€24.00
30.11.25
-65.35%
05.05.23

Could be very worthwhile Investment >20% year
buy
TG Therapeutics Inc.

Start price
Target price
Perf. (%)
€16.97
06.02.23
€27.00
31.12.25
87.64%
05.05.23

Could be very worthwhile Investment >20% year
buy
AMC Entertainment Holdings Inc.

Start price
Target price
Perf. (%)
€6.00
06.02.23
€8.00
06.02.24
-70.00%
07.02.24

Could be worthwhile Investment >10% per year
Elys Game Technology Corp

Start price
Target price
Perf. (%)
€1.18
06.02.23
-
06.02.24
-66.27%
24.04.23

Risky Investment
MyMD Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.40
06.02.23
-
06.02.24
-35.83%
24.04.23

Risky Investment
buy
Blue Apron Holdings Inc.

Start price
Target price
Perf. (%)
€13.21
06.02.23
€25.20
06.02.24
-14.57%
21.02.23

Could be very worthwhile Investment >20% year
Reshape Lifesciences Inc.

Start price
Target price
Perf. (%)
€6.89
05.02.23
-
05.02.24
-66.01%
24.04.23

Crypto Blockchain Industries S.A.

Start price
Target price
Perf. (%)
€1.38
04.02.23
-
02.05.24
-31.26%
09.02.23

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
TCR2 Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.31
04.02.23
€3.00
04.02.24
34.48%
05.05.23

Could be very worthwhile Investment >20% year
buy
Citic Resources Holdings

Start price
Target price
Perf. (%)
€0.052
03.02.23
-
03.02.24
-35.58%
24.10.23

Elys Game Technology Corp

Start price
Target price
Perf. (%)
€1.30
02.02.23
-
02.02.24
-67.08%
29.05.23

Could be very worthwhile Investment >20% year
buy
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€3.18
02.02.23
-
02.02.24
-32.40%
11.02.23

Risky Investment
buy
Sientra Inc.

Start price
Target price
Perf. (%)
€1.84
02.02.23
€3.60
02.02.24
-4.62%
06.02.23

Could be very worthwhile Investment >20% year
buy
Genel Energy

Start price
Target price
Perf. (%)
€1.46
02.02.23
-
02.02.24
-30.27%
24.10.23

Erytech Pharma S.A.

Start price
Target price
Perf. (%)
€1.11
01.02.23
-
01.02.24
-0.36%
05.02.23

Risky Investment
buy
Shougang Fushan Res. Gr.

Start price
Target price
Perf. (%)
€0.34
01.02.23
-
01.02.24
-14.71%
24.10.23

buy
Nel ASA

Start price
Target price
Perf. (%)
€1.55
31.01.23
-
28.02.23
2.68%
01.02.23

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Nel ASA

Start price
Target price
Perf. (%)
€1.54
31.01.23
€2.00
31.01.24
4.16%
06.02.23

Future proof or reliable business model
Innovative
Valuable balance sheet
ROE higher than 10% per year
buy
Lithium Americas Corp.

Start price
Target price
Perf. (%)
€22.60
31.01.23
€27.00
31.01.24
-33.22%
01.02.24

Could be worthwhile Investment >10% per year
buy
BioXcel Therapeutics Inc

Start price
Target price
Perf. (%)
€29.02
28.01.23
€45.00
31.12.25
-30.32%
05.05.23

Could be very worthwhile Investment >20% year
buy
Cardlytics Inc

Start price
Target price
Perf. (%)
€7.56
27.01.23
€7.00
27.01.24
-21.35%
13.02.23

Capable Management
Innovative
Very low/no dividend yield expected
ROE lower than 10% per year
buy
3u Holding AG

Start price
Target price
Perf. (%)
€4.05
27.01.23
-
27.01.24
35.80%
21.04.23

buy
KPS AG

Start price
Target price
Perf. (%)
€3.96
26.01.23
€5.00
26.01.24
7.58%
04.02.23

Revenue growth >5% per year expected
Standard Investments for future growth
buy
A2Z Smart Technologies Corp.

Start price
Target price
Perf. (%)
€1.41
26.01.23
€3.00
26.01.24
-5.67%
04.02.23

Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Revenue growth >5% per year expected